Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of tetrahydropyridines in preparing medicine for treating hepatitis or hepatocirrhosis

A technology for tetrahydropyrimidine and liver cirrhosis, which is applied in the application field of tetrahydropyrimidine in the preparation of medicines for treating hepatitis or liver cirrhosis, and can solve problems such as undiscovered tetrahydropyrimidine.

Inactive Publication Date: 2011-05-25
济南环肽医药科技有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there are no relevant studies and reports on the use of ectoine as an adjuvant drug for liver diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1: Research on the Effects of Ectrahydropyrimidine on Rat Liver RNA Content

[0012] 20 Wistar rats were randomly divided into 2 groups. The control group was given intragastric administration of 2ml normal saline, and the experimental group was given intragastric administration of ectoine saline solution (the dose of ectoine was 10 mg / kg body weight). / kg intraperitoneal injection 3 H-cytidine, the rats were sacrificed 48 hours after injection, and the liver was taken to measure the liver RNA content.

[0013] The results showed that the RNA content in the liver tissue of the rats in the treatment group was 2.3 times that of the control group (58.9mg / g vs 25.6mg / g), indicating that ectoine can increase the RNA content in the liver and has a good protective effect on hepatitis and cirrhosis .

Embodiment 2

[0014] Example 2: Effect of ectoine on liver albumin, prothrombinase and plasminogen levels in rats with liver cirrhosis

[0015] 20 Wistar rats were intraperitoneally injected with 40 mg / kg DMN to induce liver cirrhosis. After successful modeling, they were randomly divided into two groups, 10 rats in each group. The control group was given 2ml normal saline, and the experimental group was given ectoine saline solution (The dose of ectoine is 30 mg / kg body weight). 48 hours after administration, the rats were sacrificed, and the liver was taken to measure the levels of liver albumin, thromboplastin and plasminogen. The levels of albumin, thromboplastin, and plasminogen in the liver of rats in the experimental group were significantly higher than those in the control group, which were 39.46g / L vs 30.08g / L; 12.24g / L vs 5.57g / L; 54.92U / L vs 69.73U / L, each group compared with the normal group, P<0.05. The test results show that ectoine has a significant protective effect on live...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel application for Ectoine, namely application of the Ectoine in preparing medicines of treating hepatitis or hepatocirrhosis. The effective dosage range of the Ectoine is 0.1 to 100 mg / kg of body weight, preferably 8 to 50mg / kg of the body weight. When in use, the Ectoine adopts a mode of intravenous infusion. The experiment implemented by the inventor proves that the Ectoine can protect hepatic tissue, and inhibit the reduction of albumin, other proteins, amino acid, thrombozyme and profibrinolysin in liver and serum when the hepatitis and the hepatocirrhosis develop, thereby maintaining normal colloid osmotic pressure, delaying the generation of ascites, improving the content of RNA in the liver and achieving the aims of protecting the liver and controlling the growth of the disease of the hepatitis and the hepatocirrhosis. The Ectoine can be used for assisting treatment of the hepatitis and the hepatocirrhosis.

Description

technical field [0001] The invention relates to the application of ectoine in the preparation of medicines for treating hepatitis or liver cirrhosis. Background technique [0002] Hepatitis is an inflammation of the liver. There are many pathogenic factors, such as drug-induced hepatitis, autoimmune hepatitis, alcoholic hepatitis, and viral hepatitis. Drug metabolism is mostly completed by the endoplasmic reticulum in liver cells. The liver is not only the main site of drug metabolism, but also the main target organ of drug toxicity. If a certain type of drug is used for too long, the dose is too large, or patients with specific constitutions, it may cause liver damage; especially for patients with liver insufficiency, the possibility of damage is greater, and the resulting harmfulness Also relatively larger. Viral hepatitis is caused by hepatitis virus, mainly to damage the liver infectious disease, including A, B, C, D, E viral hepatitis. Viral hepatitis accounts for t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61P1/16A61K31/505A61P31/12
Inventor 厉保秋
Owner 济南环肽医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com